Le mésothéliome malin primitif de l´ovaire (MMPO) est une tumeur extrêmement rare qui peut se développer à partir des cellules mésothéliales. Cette néoplasie est causée principalement par une exposition à l´amiante ou à d´autres agents cancérigènes. Un bilan d´extension préopératoire comportant une tomodensitométrie, une imagerie par résonance magnétique et une tomographie par émission de positons est essentiel pour la stadification de la maladie. Le diagnostic positif anatomopathologique repose sur un panel immunohistochimique. Le MMPO reste une maladie exceptionnelle impliquant une stratégie thérapeutique multidisciplinaire, au sein de laquelle la chimiothérapie a permis d´améliorer la prise en charge et le pronostic de ces malades. Nous présentons dans cet article le cas d´une patiente ayant subi une chirurgie suboptimale, complétée par une chimiothérapie adjuvante, aboutissant à une réponse complète radiologique, avec une survie sans maladie de plus d´une année.

Background: Primary breast lymphoma is a very rare disease. The diffuse large B cell subtype is the most common histological variety. The clinical presentation is non-specific; it can be similar to that found in breast carcinoma. The diagnosis is only retained after a definitive histological analysis. The management of these lymphomas is no different from that of other localizations. We report the case of primary breast diffuse large B cells lymphoma collected at the medical oncology department of the Hassan II Hospital of Fez in a 32-year-old patient. Through this work, we will discuss the epidemiological, clinical, paraclinical, histological, therapeutic, and prognostic characteristics of these tumors. Case presentation: A 32-year-old woman consulted for a left breast nodule evolving for 3 months. Clinical examination objectified a painless mass of the left breast without inflammatory signs and homolateral axillary adenopathy of 3cm. Mammography and breast ultrasound were performed objectifying three tissue lesions measuring 26mm for the largest in the left breast, associated with homolateral axillary adenopathy. A micro biopsy was performed. Histological analysis showed breast parenchyma largely dissociated by cell proliferation of diffuse architecture with large cells. In immunohistochemistry, tumor cells were positive for the anti-CD20 antibody. An extension assessment with thoracoabdominalcomputed tomographydid not show any secondary localization outside the breast lesions found in the mammography and ultrasound. Chemotherapy with R-CHOP was decided, but the patient refused to be treated for family reasons. Conclusion: Through this work, a case of DLBCL was reported with a review of the literature. In summary, the DLBCL histological subtype is the most frequent form of mammary lymphoma. Consolidation radiotherapy after conventional chemotherapy remains the most reasonable therapeutic modality for the treatment of patients with DLBCL. Large studies are necessary to identify the factors that influence survival, to improve the management of patients with these lymphomas.

No abstract

Introduction: Non-small cell lung cancer is the most common lung cancer. Despite the therapeutic advances, its prognosis is very reserved. Aim: Determine the different prognostic factors of patients with metastatic non-small cell lung cancer and their correlation with patient survival. Methods: A retrospective study was conducted at the medical oncology department of Hassan II University Hospital in Fez, collecting 405 patients during a period of 10 years, from January 2008 to January 2018. The statistical analysis of the results was done by the software SPSS version 23, the survival was calculated by the Kaplan-Meier method. The Cox method was used to study prognostic factors. Results: The average age of our patients was 59 years, with a sex ratio M/F of 6.1. In multivariate analysis, we found a significant correlation between the deterioration of survival and an age greater than 75 years (p = 0.023), a general degraded state (p < 0.001), presence of a biological inflammatory syndrome (p < 0.001), anemia (p < 0.001) and hypoalbuminemia (p < 0.001). In addition, no significant association was found in patients with toxic habits or multiple metastatic sites. Conclusion: The prognostic factors of metastatic NSCLC in our patients were PS, age, anemia, hypoalbuminemia and inflammatory syndrome. We propose to validate all the factors identified by retrospective studies by prospective studies in order to guarantee the best chances of survival for patients.

Tyrosine kinase inhibitors (TKIs) have become a prominent option in the therapeutic arsenal of several cancers. The safety of these drugs has shown various toxicities with varying frequency and severity between different agents. The aim of this study is to describe the safety profile of different classes of TKI used in various solid tumors. It is a retrospectively descriptive study conducted in the Department of Medical Oncology at Hassan II University Hospital of Fez, Morocco, over a period of 6 years from April 2013 until April 2019. It included 216 patients who received one or more TKI for different indications in solid tumors. The average age in our series was 61.4 years with a sex ratio F/M of 1.07. Among the most used TKIs in our department according to their availability: Imatinib (32%) and sunitinib (32%). All patients received one or more tyrosine kinase inhibitors according to the indication. Kidney cancer was the most common malignancy (36%), followed by gastrointestinal stromal tumors (33%). The median duration of treatment was 15 months with extremes of 1 month and 102 months. The main side effects were: Cutaneous in 43% of patients. Digestive toxicity occurred in 36% of cases. Hematotoxicity was reported in 33% of cases. The safety profile of TKIs used in our study was comparable to their global tolerance reported in literature. More studies are needed to investigate the relationship between their toxicity and their efficacy in Moroccan population.